Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
60%
Ph phase_2
2
40%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

active_not_recruiting240%
completed360%

Recent Activity

2 active trials
Showing 5 of 5
active_not_recruitingphase_1

PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function

NCT06729853
active_not_recruitingphase_2

Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

NCT05690204
completedphase_1

SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects

NCT06678581
completedphase_2

Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients

NCT04040816
completedphase_1

Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients

NCT03857165

Clinical Trials (5)

Showing 5 of 5 trials
NCT06729853Phase 1

PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function

Active Not Recruiting
NCT05690204Phase 2

Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

Active Not Recruiting
NCT06678581Phase 1

SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects

Completed
NCT04040816Phase 2

Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients

Completed
NCT03857165Phase 1

Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5